What You Should Know:
– Pepticom, an innovator in AI-driven peptide-based therapeutics secures $6.6M in a Series A1 funding round led by Japan Israel High Tech Ventures 2 LP, with strong support from existing investors.
– The new funding will accelerate the development of Pepticom’s oral IL-17 inhibitor program, focusing on creating improved treatments for autoimmune diseases like psoriasis and psoriatic arthritis.
Revolutionizing Autoimmune Disease Treatment
Pepticom is developing two families of fully synthetic, small cyclic peptidomimetic inhibitors that target both IL-17A and IL-17F isoforms, key drivers of inflammation in autoimmune diseases. These innovative compounds, composed of non-natural amino acids, have demonstrated remarkable progress, achieving key milestones in record time and cost. Notably, they exhibit increased stability and extended half-life in both in vitro and in vivo studies.
AI-Powered Peptide Drug Discovery
Pepticom’s proprietary platform combines cutting-edge AI and machine learning with advanced biochemistry to design peptides with exceptional specificity, stability, and therapeutic potential. By leveraging a vast library of over 600 natural and non-natural amino acid building blocks, Pepticom can explore an immense chemical space of over 10⁸⁰ potential peptide structures.
This unique approach allows for the de novo design and discovery of entirely new peptidomimetic targets, offering significant advantages over traditional small molecule and biologic therapies. Pepticom’s AI-driven platform accelerates the drug discovery process, bringing innovative peptide therapies to patients faster and at a lower cost.
